Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.71 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aurantiamide Acetate SCHEMBL30004267 | 1.00 | CTSL (0.71) | CTSLCTSSCTSKPIN1PSMB5 | |
| Aurantiamide Acetate SCHEMBL31084254 | 1.00 | CTSL (0.71) | CTSLCTSSCTSKPIN1PSMB5 | |
| Aurantiamide Acetate SCHEMBL30532189 | 1.00 | CTSL (0.71) | CTSLCTSSCTSKPIN1PSMB5 | |
| Aurantiamide Acetate SCHEMBL4357298 | 1.00 | CTSL (0.71) | CTSLCTSSCTSKPIN1PSMB5 | |
| SCHEMBL24368215 | 0.93 | CTSL (0.63) | CTSLCTSSCTSKPIN1PSMB5 | |
| SCHEMBL24368216 | 0.93 | CTSL (0.63) | CTSLCTSSCTSKPIN1PSMB5 | |
| SCHEMBL24368196 | 0.92 | CTSL (0.61) | CTSLCTSSCTSKPIN1PSMB5 | |
| SCHEMBL24368183 | 0.92 | CTSL (0.61) | CTSLCTSSCTSKPIN1PSMB5 | |
| SCHEMBL28530796 | 0.92 | CTSL (0.61) | CTSLCTSSCTSKPIN1PSMB5 | |
| SCHEMBL4366379 | 0.92 | CTSL (0.60) | CTSLCTSSCTSKPIN1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436951-B1 | USE OF AURANTIAMIDE ACETATE IN THE TREATMENT OF HYPERTENSION | AKDENIZ UNIV SERMAYE ISLETME MUDURLUGU (TR) | 2026-04-08 | — | — | EP | claimed |
| CN-120053595-A | Use of compounds for the treatment of hair loss | 澳门科技大学 | 2025-05-30 | — | — | CN | claimed |
| EP-4436951-A1 | USE OF AURANTIAMIDE ACETATE IN THE TREATMENT OF HYPERTENSION | Akdeniz Universitesidoner Sermaye Isletme Mudurlugu (TR) | 2024-10-02 | — | — | EP | claimed |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-10-03 | — | — | US | claimed |
| WO-2023096617-A1 | USE OF AURANTIAMIDE ACETATE IN THE TREATMENT OF HYPERTENSION | AKDENIZ UNIVERSITESIDONER SERMAYE ISLETME MUDURLUGU (TR) | 2023-06-01 | — | — | WO | claimed |
| CN-115825281-A | Curcuma wenyujin and vinegar-processed quality evaluation method thereof | 南京中医药大学 | 2023-03-21 | — | — | CN | claimed |
| CN-114642171-A | Induction method of high-activity tripterygium wilfordii metabolite and tripterygium wilfordii active metabolic composition | 华侨大学 | 2022-06-21 | — | — | CN | claimed |
| CN-114588145-A | Application of amide alkaloid in preparation of alpha-glucosidase inhibiting drugs | 复旦大学 | 2022-06-07 | — | — | CN | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122036801-A | Crystalline forms of tenofovir alafenamide | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-3870566-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4436951-B1 | USE OF AURANTIAMIDE ACETATE IN THE TREATMENT OF HYPERTENSION | AKDENIZ UNIV SERMAYE ISLETME MUDURLUGU (TR) | 2026-04-08 | — | — | EP | disclosed |
| EP-4436951-B1 | USE OF AURANTIAMIDE ACETATE IN THE TREATMENT OF HYPERTENSION | AKDENIZ UNIV SERMAYE ISLETME MUDURLUGU (TR) | 2026-04-08 | — | — | EP | disclosed |
| CN-112500308-A | Golden acylamide alcohol ester and fluorinated derivative thereof, preparation method and application | 澳门科技大学 | 2021-03-16 | — | — | CN | disclosed |
| CN-107569528-B | Pharmaceutical composition for treating hepatitis, pharmaceutical preparation, application and preparation method | 贵州拜特制药有限公司 | 2020-09-29 | — | — | CN | disclosed |
| CN-101260091-B | Acrylamides compounds containing 1,2,3-thiadiazoles ring and having anti-hepatitis B virus activity | UNIV NANKAI | 2011-07-06 | — | — | CN | disclosed |
| CN-100480234-C | N-(N-benzoyl-phenylalanyl)-phenylalanine dipeptide derivative, and preparing method and use thereof | KEY LAB OF CHEMISTRY FOR NATUR (CN) | 2009-04-22 | — | — | CN | disclosed |
| CN-101260091-A | Acrylamides compounds containing 1,2,3-thiadiazoles ring and having anti-hepatitis B virus activity | UNIV NANKAI (CN) | 2008-09-10 | — | — | CN | disclosed |
| CN-1935779-A | N-(N-benzoyl-phenylalanyl)-phenylalanine dipeptide derivative, and its preparing method and use | NATURAL PRODUCT CHEMISTRY KEY (CN) | 2007-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR6 | CTSL 1240/4885CTSS 3582/4885CTSK 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.